ZIREX Film-coated tablet Ref.[28273] Active ingredients: Cetirizine

Source: Υπουργείο Υγείας (CY)  Publisher: Remedica Ltd, Aharnon Str., Limassol Industrial Estate, 3056 Limassol, Cyprus

4.1. Therapeutic indications

Cetirizine is indicated in adults and paediatric patients 6 years and above:

  • for the relief of nasal and ocular symptoms of seasonal and perennial allergic rhinitis.
  • for the relief of symptoms of chronic idiopathic urticaria.

4.2. Posology and method of administration

Posology

10 mg once daily (1 tablet).

Special population

Elderly subjects

Data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function is normal.

Renal impairment

There are no data to document the efficacy/safety ratio in patients with renal impairment. Since cetirizine is mainly excreted via renal route (see section 5.2), in cases no alternative treatment can be used, the dosing intervals must be individualized according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient’s creatinine clearance (CLcr) in mL/min is needed. The CLcr (mL/min) may be estimated from serum creatinine (mg/dl) determination using the following formula:

Dosing adjustments for adult patients with impaired renal function:

GroupCreatinine clearance (mL/min) Dosage and frequency
Normal≥8010 mg once daily
Mild50-7910 mg once daily
Moderate30-495 mg once daily
Severe<305 mg once every 2 days
End-stage renal disease – Patients undergoing dialysis<10Contraindicated

Hepatic impairment

No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of the dose is recommended (see Patients with moderate to severe renal impairment above).

Paediatric population

The tablet formulation should not be used in children under 6 years of age as it does not allow the necessary dose adjustments.

Children aged from 6 to 12 years: 5 mg twice daily (a half tablet twice daily).

Adolescents above 12 years: 10 mg once daily (1 tablet)

In paediatric patients suffering from renal impairment, the dose will have to be adjusted on an individual basis taking into account the renal clearance, age and body weight of the patient.

Method of administration

Oral administration.

The tablets need to be swallowed with a glass of liquid.

4.9. Overdose

Symptoms

Symptoms observed after an overdose of cetirizine are mainly associated with CNS effects or with effects that could suggest an anticholinergic effect.

Adverse events reported after an intake of at least 5 times the recommended daily dose are: confusion, diarrhoea, dizziness, fatigue, headache, malaise, mydriasis, pruritus, restlessness, sedation, somnolence, stupor, tachycardia, tremor and urinary retention.

Management

There is no known specific antidote to cetirizine.

Should overdose occur, symptomatic or supportive measures are recommended. Gastric lavage should be considered following ingestion of the drug.

Cetirizine is not effectively removed by haemodialysis.

6.3. Shelf life

5 years.

6.4. Special precautions for storage

Store below 25°C. Protect from light and moisture.

6.5. Nature and contents of container

PVC/Aluminium blisters Pack-sizes of 10, 30, 100 and 1000 film-coated tablets.
PP containers with PE closure. Pack-size of 1000 film-coated tablets.

Not all pack sizes may be marketed.

6.6. Special precautions for disposal and other handling

No special requirements.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.